Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hematologic Disease Immunotherapy
Data on hematologic disease immunotherapy detailed by R. Giancola and co-authors
May 21st, 2008
Research findings, 'Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer,' are discussed in a new report. According to recent research from Pescara, Italy, "Cytokine-induced killer (CIK) cells are a heterogeneous population of immune cells derived from peripheral blood lymphocytes with a high proliferative potential ex vivo. This study shows a rapid and reproducible protocol for adoptive immunotherapy with CIK cells in patients with hematologic malignancies." "For this purpose a new automatic cell processing device (CytoMate, Baxter Oncology) was tested to improve...
Source: Immunotherapy Weekly (2008-05-21)
|
